HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cipla Switches Fexofenadine For Hives From Rx-To-OTC Status In The UK

Executive Summary

UK hives sufferers can now buy a specific OTC medicine for their condition thanks to a successful Rx-to-OTC switch from Cipla. 

You may also be interested in...



Sanofi’s Nasacort Hay Fever Spray Latest In Post-Brexit UK Switch Boom

Sanofi's Nasacort Allergy Relief hay fever spray is the latest in a flood of reclassifications in the UK since the beginning of the year when the country left the European Union.

Sanofi Switch Gives UK Hay Fever Sufferers Additional Mass Market Option

Sanofi has switched its Allevia hay fever tablets (fexofenadine hydrochloride) in the UK, from prescription-only to general sales list status. 

EMA Recommends EU-Wide Desloratadine Switch

Teva subsidiary Ratiopharm has secured EMA's backing for the EU-wide switch of allergy drug desloratadine, representing the second reclassification approved by the regulator this year.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS151324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel